You are here
Regulated information
|
September 02, 2020
Avis de mise à disposition du Rapport Financier Semestriel 2020
|
|
September 02, 2020
Interim Financial Report 2020
|
|
September 02, 2020
First-Half 2020 Results
|
|
July 09, 2020
Second-Quarter 2020 Business Performance Preannouncement
|
|
February 26, 2020
bioMérieux – 2019 Financial Results
|
|
July 27, 2015
These information have been shifted to the Registration Document, now called Universal Registration Document
|
|
May 13, 2014
bioMérieux Rapport du Président 2013
|
|
April 22, 2013
Avis de mise à disposition du Rapport du Président du Conseil d'administration sur le contrôle interne
|
|
April 22, 2013
Report of the Chairman of the Board of Directors on Corporate Governance and Internal control report
|
|
April 30, 2010
Rapport sur le gouvernement d'entreprise et le contrôle interne 2009
|
|
July 27, 2015
These information have been shifted to the Registration Document, now called Universal Registration Document
|
|
May 13, 2014
bioMérieux Honoraires des commissaires aux comptes 2013
|
|
April 15, 2013
Honoraires des Commissaires aux Comptes 2012
|
|
April 28, 2010
Honoraires des Commissaires aux Comptes 2009 et 2008
|
|
June 11, 2009
Prospectus 2008
|
|
November 04, 2020
October 2020 - Declaration about number of shares issued and number of voting rights
|
|
October 05, 2020
September 2020 - Declaration about number of shares issued and number of voting rights
|
|
September 03, 2020
August 2020 - Declaration about number of shares issued and number of voting rights
|
|
August 06, 2020
July 2020 - Declaration about number of shares issued and number of voting rights
|
|
July 08, 2020
June 2020 - Declaration about number of shares issued and number of voting rights
|
|
October 10, 2013
Communiqué de mise à disposition du Prospectus Emission Obligataire visé par l'AMF Octobre 2013
|
|
May 07, 2004
Document de Base
|
|
December 02, 2020
BIOASTER, Université de Technologie de Compiègne, Hospices Civils de Lyon and bioMérieux formalize strategic collaboration to conduct Next Generation Sequencing technology evaluation in microbiology
|
|
November 16, 2020
bioMérieux announces the expansion of the CE marking of its molecular biology ARGENE® SARS-CoV-2 diagnostic test to include saliva specimens.
|
|
October 22, 2020
bioMérieux – Third-Quarter 2020 Business Review
|
|
October 08, 2020
AMSP partners with bioMérieux to facilitate supply of high-quality COVID-19 diagnostics
|
|
July 16, 2020
Launch of BIOFIRE® MYCOPLASMA test for mycoplasma detection in biopharmaceutical products
|
|
May 22, 2020
Notice of information related to preparatory documents for the Ordinary and Extraordinary Shareholders’ Meeting of June 30, 2020
|
|
October 30, 2020
Disclosure of trading in own shares on October 30, 2020
|
|
September 23, 2020
Disclosure of trading in own shares on September 23, 2020
|
|
September 16, 2020
Disclosure of trading in own shares on September 16, 2020
|
|
July 27, 2020
AG 2020-Descriptif du programme de rachat d'actions
|
|
July 10, 2020
Biannual report on bioMérieux's liquidity
|
No regulated information available